Hangzhou DAC Biotechnology | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Data insights

8 July 2025

Chia Tai broadens its biparatopic breast cancer approach

The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.

Subscribe to Hangzhou DAC Biotechnology